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OBJECTIVES: Pemetrexed (Pem) was recently approved in the US for maintenance 
treatment of patients with advanced nonsquamous non-small cell lung cancer 
(NSCLC) whose disease has not progressed after 4 cycles of platinum-based ﬁrst-line 
chemotherapy. The objective of this study was to estimate the budgetary impact of 
adopting Pem in this new indication from a US health plan’s perspective. METHODS: 
A deterministic model was developed from the perspective of a one-million member 
health plan. A survey of 300 oncologists was used to estimate the market shares of 
maintenance therapies before and after introducing Pem. Drug costs were obtained 
from Medicare reimbursement rates; non-drug costs from a claims database analysis. 
The number of maintenance-eligible patients was calculated from SEER incidence rates 
and the estimated proportions of NSCLC patients beginning and completing platinum-
based ﬁrst-line chemotherapy with stable disease or better. Model outputs included 
annual health plan cost, and costs per member per month (PMPM) and per treated 
member per month (PTMPM). One-way sensitivity analyses assessed the effect of 
changing input values. RESULTS: Assuming a 50% increase in the number of patients 
receiving maintenance therapy from 26 to 39 in a one-million member health plan, 
the model estimates a total annual cost increase of $365,323. Savings from patients 
who would have continued ﬁrst-line therapy at an annual cost of $48,253 result in 
an estimated net budget impact of $317,070 translating into a PTMPM of $679.22 
and PMPM of $0.026. The PMPM is sensitive only to the expected increase in main-
tenance use. CONCLUSIONS: The adoption of Pem as maintenance therapy is antici-
pated to increase the number of patients receiving maintenance treatment while 
reducing the number of patients continuing ﬁrst-line therapy. This increase in main-
tenance therapy utilization is expected to increase the budget impact for a health plan 
by less than $0.03 per member per month.
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OBJECTIVES: Evaluate the budget impact of substituting the current recommendation 
of the Colombian National Cancer Institute (CNCI) for the early detection of breast 
cancer in Colombia for an organized screening program based on annual mammog-
raphy for women 40–69 years (OgSP). METHODS: A previous cost-effectiveness 
study funded by the CNCI showed that the OgSP was more effective but more expen-
sive than the current recommendation of the CNCI, opportunistic screening based on 
biennial mammography for women 50–69 years and annual breast clinical exam for 
women 30–69 years (OpSP). A spreadsheet model following the ISPOR task force 
recommendations was developed to compute the annual, average, total, per-member-
per-month (PMPM) and per-treated-member-per-month (PTMPM) costs and budget 
impact of the OgSP in four years. All inputs were based on local information and 
included Colombian population growth, age and gender distributions, breast cancer 
incidence rates in Colombian women and number of women eligible for breast cancer 
screening; mammography and clinical exam speciﬁcity, sensitivity and costs; oppor-
tunistic and organized program coverage and costs, and diagnosis conﬁrmation exams 
and breast cancer treatment costs. RESULTS: Total cost PTMPM was estimated to be 
$121 for the OpSP. With the new proportional share, it would increase to $241, a 
99% increase. 98% of the costs came from the greater number of mammograms given 
the nature of the OgSP, and the greater number diagnosis conﬁrmation exams and 
treated women given the major effectiveness of the OgSP in breast cancer detection. 
Results remained favorable for OpSP under all sensitivity analyses. CONCLUSIONS: 
The impact of substituting the current OpSP for the OgSP will yield very high costs 
to the Colombian health care system budget. Decision makers should consider other 
strategies for the early detection of breast cancer screening, more effective than the 
current OpSP and affordable, using the developed model to evaluate the budget impact 
of the new streategies under consideration.
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OBJECTIVES: To estimate the impact of the introduction of everolimus on drug 
spending for a hypothetical health plan in the US. METHODS: A cross-sectional 
model was developed using a one-year time horizon. The model included National 
Comprehensive Cancer Network guideline-recommended advanced RCC treatments: 
bevacizumab, IFN, IL-2, sorafenib, sunitinib, temsirolimus and everolimus. Disease 
prevalence rates were based on literature and Surveillance Epidemiology and End 
Results. Monthly market share data prior to the introduction of everolimus were based 
on the data from IntrinsiQ (November 2007–October 2008). Due to a lack of com-
parative trials, adverse event rates in similar patient populations are unavailable. As 
such, this model assessed only pharmacy budget, with relevant costs including that of 
drug therapy and administration. Drug costs were based on Wholesale Acquisition 
Costs (2009). Furthermore, as best supportive care and palliative care alongside each 
treatment were assumed to be comparable, their costs were not presented in the model. 
The model assessed the annual incremental impact on pharmacy expenditure under 
the assumption that everolimus replaces drugs currently being used after failure of 
treatment with sunitinib or sorafenib such as bevacizumab, temsirolimus, sunitinib, 
sorafenib, interferon-alpha, and interleukin-2. RESULTS: For a hypothetical health 
plan with 1,000,000 members, the model estimated a prevalence of 203 patients with 
advanced RCC. Under various scenarios, assuming that 24% of advanced RCC 
patients are placed on everolimus, the impact on pharmacy expenditure ranged from 
a savings of $50,093 annually or $0.05 per patient per year (PMPY) to an increase 
of $43,749 annually or $0.04 PMPY. CONCLUSIONS: Under the current model 
assumptions, everolimus has a minimal impact on pharmacy expenditure for a US 
health plan. It may offer cost savings when replacing higher-cost therapies.
PCN28
BUDGET IMPACT ANALYSIS OF NEW PROSTATE-SPECIFIC ANTIGEN 
ASSAY AND INDEX FOR PROSTATE CANCER DETECTION
Nichol MB1, Wu J1, An JJ1, Huang JT2, Frencher SK3, Jacobsen SJ4
1University of Southern California, Los Angeles, CA, USA, 2Beckman Coulter Inc, Brea, CA, 
USA, 3UCLA, RAND Institute, Los Angeles, CA, USA, 4Kaiser Permanente Southern 
California, Pasadena, CA, USA
OBJECTIVES: To evaluate the budget impact of adding a new assay and prostate 
cancer (Pca) detection index to conventional prostate-speciﬁc antigen (PSA) blood test 
for detecting Pca. METHODS: Access Hybritech p2PSA is a precursor form of PSA. 
It is a new assay and being tested for use with PSA and free PSA to calculate a Pca 
detection index to determine the relative risk of Pca. The index is in development for 
U.S. market pending Food and Drug Administration approval. We constructed two 
budget impact models using PSA cutoff values of 2 ng/ml (Model1) and 4 ng/ml 
(Model2) for recommending biopsy in a hypothetical health plan with 100,000 male 
members aged 50 to 75 years old. Probabilities of positive PSA test results and cancer 
detection were derived from the published literature as well as a simulation study of 
the Pca detection index. We calculated the budgetary impact after introducing the Pca 
detection index on the one-year expected total costs for Pca detection. Sensitivity 
analysis was performed to examine the robustness of results. RESULTS: After intro-
ducing the Pca detection index, the number of cancer cases detected decreased by 50 
and 30, in Model1 and Model2, respectively. The savings on total costs for the indi-
viduals with a positive PSA test were $284,151 in Model1, and $109,387 in Model2. 
The budget impacts on total costs for the individuals with a negative test were $22,127 
(Model1) and $8,518 (Model2). The savings on expected one-year cost for Pca detec-
tion were $262,024 (or $0.22 per-member-per-month (PMPM)) in Model1, $100,869 
(or $0.08 PMPM) in Model2. CONCLUSIONS: The model with PSA cutoff >2 ng/
ml produced higher cost savings than the model with cutoff >4 ng/ml. However, a 
small short-term reduction in the number of positive PSA tests was also observed.
PCN29
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OBJECTIVES: There is available evidence from a systematic review with meta-analysis 
that MFR and SFR have comparative efﬁcacy in the treatment of bone metastasis. We 
aimed to compare the costs of MFR (20 Gy in ﬁve applications or 30 Gy in ten 
applications) versus SFR in the treatment of bone metastasis and pain control and 
determine the budgetary impact for PHC providers in Brazil. METHODS: all patients 
submitted to antalgic palliative radiotherapy for bone metastasis, from January 2009 
to December 2009, were retrieved from Evidencias Cancer Treatment Database (www.
evidencias.com.br). We evaluated a 50.000 lives’ HPC and projected the results for a 
1,000,000 population. We used data from the above mentioned SR with MA to 
support the calculations of the projected costs for both types of treatment. RESULTS: 
The annual incidence of patients in need of antalgic palliative radiotherapy for bone 
metastasis was 140/per million. The SR with MA determined that MFR and SFR are 
equally effective in palliating bone pain with the same risks of complications. However 
SFR increases the need of re-treatment (RR = 2.5; CI95% 1.76 to 3.56), or 19.9% 
for SFR versus 7.8% for MFR (level of evidence 1b). We calculated the cost of each 
treatment as MFR USD 2,456,11 /patient and SFR USD 1,734,98 /patient. The pro-
jected costs in a population of 1 million insured lives including re-treatment costs was 
USD 370,872,77 for MFR versus USD 291,476,66 for SFR. The difference of USD 
79,396,11 represents USD 0,08/per life insured/per year. CONCLUSIONS: Since both 
types of radiotherapy are equally effective, and SFR provides an economy of USD 0.08 
per life/per year, it should be the preferred choice.
